CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Won the “Best Pharmaceutical and Medical Company” from Golden Hong Kong Listed Companies
2022-07-08

Won the “Best Pharmaceutical and Medical Company” from Golden Hong Kong Listed Companies

Recognized as the “Honored Company” and the top three of “Best ESG” by the Institutional Investors Magazine

Recognized as the “Honored Company” and the top three of “Best ESG” by the Institutional Investors Magazine

MSCI-ESG rating maintained “AA” for two consecutive years, leading the industry globally

MSCI-ESG rating maintained “AA” for two consecutive years, leading the industry globally

Listed in “CSR Ranking of Pharmaceutical Enterprises in 2020” by Southern Weekly

Listed in “CSR Ranking of Pharmaceutical Enterprises in 2020” by Southern Weekly

Awarded the “Most Socially Responsible Listed Company” of Jinqilin Awards held by Sina Finance

Awarded the “Most Socially Responsible Listed Company” of Jinqilin Awards held by Sina Finance

Selected for “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies”
2022-07-15

Selected for “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies”

Shenzhen Kangzhe was selected for “Shenzhen Top 500 Enterprises” and “Top 100 Corporate Taxpayers in Nanshan District”
2022-07-08

Shenzhen Kangzhe was selected for “Shenzhen Top 500 Enterprises” and “Top 100 Corporate Taxpayers in Nanshan District”

Initiated the model of strategic investment in Chinese Biotech;  made equity investment in Trinomab and established a joint venture to develop 4 fully human antibody novel drugs

Initiated the model of strategic investment in Chinese Biotech; made equity investment in Trinomab and established a joint venture to develop 4 fully human antibody novel drugs

Initiated the model of innovative products customization and entrusted a CRO for customized development of 4 innovative medicines

Initiated the model of innovative products customization and entrusted a CRO for customized development of 4 innovative medicines

New Drug Applications of Diazepam Nasal Spray, Tildrakizumab Solution for Injection, and Methotrexate Injection, Pre-filled Syringe (for psoriasis) were accepted by China NMPA

New Drug Applications of Diazepam Nasal Spray, Tildrakizumab Solution for Injection, and Methotrexate Injection, Pre-filled Syringe (for psoriasis) were accepted by China NMPA

Obtained clinical trial notices of Desidustat Tablets, Methotrexate Injection, Pre-filled Syringe (for RA), and Methylthioninium Chloride Enteric-coated Sustained-release Tablets from China NMPA

Obtained clinical trial notices of Desidustat Tablets, Methotrexate Injection, Pre-filled Syringe (for RA), and Methylthioninium Chloride Enteric-coated Sustained-release Tablets from China NMPA

CMS Skinhealth, the dermatology and medical aesthetic company, was officially established; acquired three dermatology and medical aesthetic specialty companies including Luqa Ventures, Carnation Medical Technology and Xuli Medical, and achieved collaboration with OVMEDI; acquired assets or products rights of a number of products including Aethoxysklerol, Vmonalisa HA filler, FUBA5200 Focused Ultrasound Body Contouring System and Omega VL Thread Carving Products in Mainland China and/or other countries or regions

CMS Skinhealth, the dermatology and medical aesthetic company, was officially established; acquired three dermatology and medical aesthetic specialty companies including Luqa Ventures, Carnation Medical Technology and Xuli Medical, and achieved collaboration with OVMEDI; acquired assets or products rights of a number of products including Aethoxysklerol, Vmonalisa HA filler, FUBA5200 Focused Ultrasound Body Contouring System and Omega VL Thread Carving Products in Mainland China and/or other countries or regions

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号